BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation

Blood

Volumn 117, Issue 26, 2011, Pages 7145-7154

  Vogler, Meike ^a   Hamali, Hassan A ^b   Sun, Xiao Ming ^a   Bampton, Edward T W ^a   Dinsdale, David ^a   Snowden, Roger T ^a   Dyer, Martin J S ^a   Goodall, Alison H ^b   Cohen, Gerald M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CALCIUM; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

EID: 79959828108     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-344812     Document Type: Article

References (48)

1. Zauli G, Vitale M, Falcieri E, et al. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood. 1997;90(6):2234-2243. (Pubitemid 27392707)
2. Kuwana T, Newmeyer DD. Bcl-2-family proteins and the role of mitochondria in apoptosis. Curr Opin Cell Biol. 2003;15(6):691-699. (Pubitemid 37487962)
3. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47-59.
4. Szegezdi E, Macdonald DC, Ni Chonghaile T, Gupta S, Samali A. Bcl-2 family on guard at the ER. Am J Physiol Cell Physiol. 2009;296(5):C941-C953.
5. Rong Y, Distelhorst CW. Bcl-2 protein family members: versatile regulators of calcium signaling in cell survival and apoptosis. Annu Rev Physiol. 2008;70:73-91. (Pubitemid 351738172)
6. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7(12):989-1000.
7. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 2009;16(3):360-367.
8. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677-681. (Pubitemid 40825512)
9. Park CM, Bruncko M, Adickes J, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem. 2008;51(21):6902-6915.
10. Wierda G, Roberts P, Brown R, et al. Pharmacokinetics, safety and antitumor activity of ABT-263 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Hematologica. 2009;94(suppl 2):138. Abstract 0350.
11. Tse C, Shoemaker AR, Adickes J, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421-3428.
12. Roberts AW, Gandhi L, O'Connor OA, et al. Reduction in platelet counts as a mechanistic biomarker and guide for adaptive dose-escalation in phase 1 studies of the Bcl-2 family inhibitor ABT-263. J Clin Oncol. 2008;26. Abstract 3542.
13. Zhang H, Nimmer PM, Tahir SK, et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007;14(5):943-951. (Pubitemid 46655455)
14. Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173-1186. (Pubitemid 46427871)
15. Shcherbina A, Remold-O'Donnell E. Role of caspase in a subset of human platelet activation responses. Blood. 1999;93(12):4222-4231. (Pubitemid 29279264)
16. Vanags DM, Orrenius S, Aguilar-Santelises M. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol. 1997;99(4):824-831. (Pubitemid 28047145)
17. Wolf BB, Goldstein JC, Stennicke HR, et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood. 1999;94(5):1683-1692. (Pubitemid 29411318)
18. Leytin V, Freedman J. Platelet apoptosis in stored platelet concentrates and other models. Transfus Apher Sci. 2003;28:285-295. (Pubitemid 36506504)
19. Bertino AM, Qi XQ, Li J, Xia Y, Kuter DJ. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion. 2003;43(7):857-866. (Pubitemid 36753934)
20. Wagner KU, Claudio E, Rucker EB 3rd, et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development. 2000;127(22):4949-4958.
21. Coupland LA, Cromer D, Davenport MP, Parish CR. A novel fluorescent-based assay reveals that thrombopoietin signaling and Bcl-X(L) influence, respectively, platelet and erythrocyte lifespans. Exp Hematol. 2010;38(6):453-461.
22. Lopez JJ, Salido GM, Pariente JA, Rosado JA. Thrombin induces activation and translocation of Bid, Bax and Bak to the mitochondria in human platelets. J Thromb Haemost. 2008;6(10):1780-1788.
23. Lin KH, Chang HC, Lu WJ, et al. Comparison of the relative activities of inducing platelet apoptosis stimulated by various platelet-activating agents. Platelets. 2009;20(8):575-581.
24. Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood. 2009(3):114:663-666.
25. Dasgupta SK, Argaiz ER, Mercado JE, et al. Platelet senescence and phosphatidylserine exposure. Transfusion. 2010;50:2167-2175.
26. Morton LF, Hargreaves PG, Farndale RW, Young RD, Barnes MJ. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triplehelical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem J. 1995;306(2):337-344.
27. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15. (Pubitemid 37449290)
28. Kienast J, Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood. 1990;75(1):116-121. (Pubitemid 20031498)
29. White JG. Electron microscopy methods for studying platelet structure and function. Methods Mol Biol. 2004;272:47-63.
30. Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149-1159.
31. Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res. 2010;16(16):4217-4225.
32. Jobe SM, Wilson KM, Leo L, et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood. 2008;111(3):1257-1265. (Pubitemid 351213408)
33. Bevers EM, Comfurius P, van Rijn JL, Hemker HC, Zwaal RF. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem. 1982;122(2):429-436. (Pubitemid 12152078)
34. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326(1):1-16. (Pubitemid 27386911)
35. Shrivastava M. The platelet storage lesion. Transfus Apher Sci. 2009;41(2):105-113.
36. Gerasimenko J, Ferdek P, Fischer L, Gukovskaya AS, Pandol SJ. Inhibitors of Bcl-2 protein family deplete ER Ca2+ stores in pancreatic acinar cells. Pflugers Arch. 2010;460(5):891-900.
37. Hermanson D, Addo SN, Bajer AA, et al. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Mol Pharmacol. 2009;76(3):667-678.
38. Metcalfe P, Williamson LM, Reutelingsperger CP, Swann I, Ouwehand WH, Goodall AH. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol. 1997;98(1):86-95. (Pubitemid 27348800)
39. Brown SB, Clarke MC, Magowan L, Sanderson H, Savill J. Constitutive death of platelets leading to scavenger receptor-mediated phagocytosis: a caspase-independent cell clearance program. J Biol Chem. 2000;275(8):5987-5996. (Pubitemid 30115249)
40. Karpatkin S. Heterogeneity of human platelets: II. Functional evidence suggestive of young and old platelets. J Clin Invest. 1969;48(6):1083-1087.
41. Alberio L, Friese P, Clemetson KJ, Dale GL. Collagen response and glycoprotein VI function decline progressively as canine platelets age in vivo. Thromb Haemost. 2002;88(3):510-516. (Pubitemid 35021612)
42. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007;67(7):2908-2911. (Pubitemid 46724822)
43. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389-399. (Pubitemid 44711953)
44. Vogler M, Butterworth M, Majid A, et al. Concurrent upregulation of BCL-XL and BCL2A1 induces ∼ 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113(18):4403-4413.
45. Kodama T, Takehara T, Hikita H, et al. BH3-only activator proteins, Bid and Bim, are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem. 2011;286(16):13905-13913.
46. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest. 2007;117(1):112-121. (Pubitemid 46048458)
47. Goodall AH, Burns P, Salles I, et al. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood. 2010;116(22):4646-4656.
48. Watkins NA, Gusnanto A, de Bono B, et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood. 2009;113(19):e1-e9.